Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR

Chih-Cheng Chang, Ting Lieh Hsieh, Tung Yu Tiong, Chi Hao Hsiao, Andrea Tung Qian Ji, Wei Tse Hsu, Oscar K. Lee, Jennifer H. Ho

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lung fibrosis is a poor prognostic factor for pulmonary adenocarcinoma, and the effect of a rigid microenvironment on cancer behavior is unclear. We cultured A549 cells on matrices of 0.2, 2, and 25kPa to mimic the rigidities of normal lung parenchyma, progressive fibrotic change, and lung fibrosis, respectively. Lung tissue from patients with pulmonary adenocarcinoma was used to confirm the invitro findings. Increased matrix rigidity promoted cell proliferation and upregulated the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), and Snail expression in A549 cells. A549 cells became more resistant to the EGFR inhibitor (Erlotinib) and c-Met inhibitor (PHA-665752) when matrix rigidity increased; however, a high concentration of PHA-665752 reversed the rigidity-induced morphological pleomorphism. In human lung tissue, expression of type I collagen was more consistent with clinical fibrosis than the expression of alpha-smooth muscle antibody was. c-Met- and Snail-expressing tumor cells, rather than EGFR-experssing cells, were localized with lung parenchyma rich in type I collagen. Our findings suggest that c-Met causes the rigidity-induced biophysical reaction in pulmonary adenocarcinoma. Treatment targeting both EGFR and c-Met should be considered for patients with lung fibrosis and who are abundant type I collagen expression in the tumor mass.

Original languageEnglish
Pages (from-to)141-150
Number of pages10
JournalBiomaterials
Volume60
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Aptitude
Epidermal Growth Factor Receptor
Drug Resistance
Rigidity
Lung
Collagen Type I
Collagen
Pharmaceutical Preparations
Fibrosis
Tumors
Proto-Oncogene Proteins c-met
Tissue
Cell proliferation
Antibodies
Muscle
Tumor Microenvironment
Snails
Cells
Adenocarcinoma of lung
Epidermal Growth Factor

Keywords

  • Adenocarcinoma
  • C-Met
  • Drug resistance
  • Epidermal growth factor receptor
  • Lung fibrosis
  • Matrix rigidity

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR. / Chang, Chih-Cheng; Hsieh, Ting Lieh; Tiong, Tung Yu; Hsiao, Chi Hao; Ji, Andrea Tung Qian; Hsu, Wei Tse; Lee, Oscar K.; Ho, Jennifer H.

In: Biomaterials, Vol. 60, 01.08.2015, p. 141-150.

Research output: Contribution to journalArticle

@article{87779bd3aad84b98998a4d68cea7709b,
title = "Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR",
abstract = "Lung fibrosis is a poor prognostic factor for pulmonary adenocarcinoma, and the effect of a rigid microenvironment on cancer behavior is unclear. We cultured A549 cells on matrices of 0.2, 2, and 25kPa to mimic the rigidities of normal lung parenchyma, progressive fibrotic change, and lung fibrosis, respectively. Lung tissue from patients with pulmonary adenocarcinoma was used to confirm the invitro findings. Increased matrix rigidity promoted cell proliferation and upregulated the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), and Snail expression in A549 cells. A549 cells became more resistant to the EGFR inhibitor (Erlotinib) and c-Met inhibitor (PHA-665752) when matrix rigidity increased; however, a high concentration of PHA-665752 reversed the rigidity-induced morphological pleomorphism. In human lung tissue, expression of type I collagen was more consistent with clinical fibrosis than the expression of alpha-smooth muscle antibody was. c-Met- and Snail-expressing tumor cells, rather than EGFR-experssing cells, were localized with lung parenchyma rich in type I collagen. Our findings suggest that c-Met causes the rigidity-induced biophysical reaction in pulmonary adenocarcinoma. Treatment targeting both EGFR and c-Met should be considered for patients with lung fibrosis and who are abundant type I collagen expression in the tumor mass.",
keywords = "Adenocarcinoma, C-Met, Drug resistance, Epidermal growth factor receptor, Lung fibrosis, Matrix rigidity",
author = "Chih-Cheng Chang and Hsieh, {Ting Lieh} and Tiong, {Tung Yu} and Hsiao, {Chi Hao} and Ji, {Andrea Tung Qian} and Hsu, {Wei Tse} and Lee, {Oscar K.} and Ho, {Jennifer H.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.biomaterials.2015.04.058",
language = "English",
volume = "60",
pages = "141--150",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",

}

TY - JOUR

T1 - Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR

AU - Chang, Chih-Cheng

AU - Hsieh, Ting Lieh

AU - Tiong, Tung Yu

AU - Hsiao, Chi Hao

AU - Ji, Andrea Tung Qian

AU - Hsu, Wei Tse

AU - Lee, Oscar K.

AU - Ho, Jennifer H.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Lung fibrosis is a poor prognostic factor for pulmonary adenocarcinoma, and the effect of a rigid microenvironment on cancer behavior is unclear. We cultured A549 cells on matrices of 0.2, 2, and 25kPa to mimic the rigidities of normal lung parenchyma, progressive fibrotic change, and lung fibrosis, respectively. Lung tissue from patients with pulmonary adenocarcinoma was used to confirm the invitro findings. Increased matrix rigidity promoted cell proliferation and upregulated the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), and Snail expression in A549 cells. A549 cells became more resistant to the EGFR inhibitor (Erlotinib) and c-Met inhibitor (PHA-665752) when matrix rigidity increased; however, a high concentration of PHA-665752 reversed the rigidity-induced morphological pleomorphism. In human lung tissue, expression of type I collagen was more consistent with clinical fibrosis than the expression of alpha-smooth muscle antibody was. c-Met- and Snail-expressing tumor cells, rather than EGFR-experssing cells, were localized with lung parenchyma rich in type I collagen. Our findings suggest that c-Met causes the rigidity-induced biophysical reaction in pulmonary adenocarcinoma. Treatment targeting both EGFR and c-Met should be considered for patients with lung fibrosis and who are abundant type I collagen expression in the tumor mass.

AB - Lung fibrosis is a poor prognostic factor for pulmonary adenocarcinoma, and the effect of a rigid microenvironment on cancer behavior is unclear. We cultured A549 cells on matrices of 0.2, 2, and 25kPa to mimic the rigidities of normal lung parenchyma, progressive fibrotic change, and lung fibrosis, respectively. Lung tissue from patients with pulmonary adenocarcinoma was used to confirm the invitro findings. Increased matrix rigidity promoted cell proliferation and upregulated the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), and Snail expression in A549 cells. A549 cells became more resistant to the EGFR inhibitor (Erlotinib) and c-Met inhibitor (PHA-665752) when matrix rigidity increased; however, a high concentration of PHA-665752 reversed the rigidity-induced morphological pleomorphism. In human lung tissue, expression of type I collagen was more consistent with clinical fibrosis than the expression of alpha-smooth muscle antibody was. c-Met- and Snail-expressing tumor cells, rather than EGFR-experssing cells, were localized with lung parenchyma rich in type I collagen. Our findings suggest that c-Met causes the rigidity-induced biophysical reaction in pulmonary adenocarcinoma. Treatment targeting both EGFR and c-Met should be considered for patients with lung fibrosis and who are abundant type I collagen expression in the tumor mass.

KW - Adenocarcinoma

KW - C-Met

KW - Drug resistance

KW - Epidermal growth factor receptor

KW - Lung fibrosis

KW - Matrix rigidity

UR - http://www.scopus.com/inward/record.url?scp=84930423883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930423883&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.04.058

DO - 10.1016/j.biomaterials.2015.04.058

M3 - Article

VL - 60

SP - 141

EP - 150

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -